For Biohaven Ltd. (BHVN), a global clinical-stage biopharmaceutical company focused on developing life-changing therapies for rare and common diseases, the second half of 2026 could be a defining chapter, with pivotal data readouts poised to shape the future of its diverse pipeline.
At the core of this innovation are its novel platforms, MoDE and TRAP, designed to target the root causes of autoimmune diseases. MoDE targets a class of proteins implicated in disease pathogenesis, while TRAP selectively removes disease-causing proteins while leaving the rest of the immune system intact.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.